{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T22:03:06Z","timestamp":1764540186354,"version":"3.46.0"},"reference-count":44,"publisher":"Practical Medicine Publishing House","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Oncohematology"],"abstract":"<jats:p>The concept of total curability of Hodgkin\u2019s lymphoma was introduced as early as in 1970s. However, 10\u201330\u00a0% of patients develop relapses; in addition, resistant tumors cannot be excluded. A high-dose chemotherapy with autologous hematopoietic stem cell transplantation is a modern treatment standard for relapses and refractory Hodgkin\u2019s lymphomas. However, long-term remissions are achieved only in a half of these patients. The toxicity of effective first-line treatment regimens and insufficient effectiveness of regimens prescribed for relapses and refractory disease are the reason for further search of new therapeutic options for this malignant tumor. Invention of an immunoconjugate, brentuximab vedotin, became one of the new steps in the treatment of Hodgkin\u2019s lymphomas. This review presents data on the pharmacological properties of the drug, the mechanism of the anti-tumor effect, as well as results of large international, randomized clinical trials.<\/jats:p>","DOI":"10.21320\/2500-2139-2016-9-4-398-405","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T13:54:05Z","timestamp":1482155645000},"page":"398-405","source":"Crossref","is-referenced-by-count":3,"title":["Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin\u2019s Lymphomas","\u0411\u0440\u0435\u043d\u0442\u0443\u043a\u0441\u0438\u043c\u0430\u0431 \u0432\u0435\u0434\u043e\u0442\u0438\u043d: \u043d\u043e\u0432\u044b\u0435 \u0432\u043e\u0437\u043c\u043e\u0436\u043d\u043e\u0441\u0442\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0440\u0435\u0446\u0438\u0434\u0438\u0432\u043e\u0432 \u0438 \u0440\u0435\u0444\u0440\u0430\u043a\u0442\u0435\u0440\u043d\u044b\u0445 \u0444\u043e\u0440\u043c \u043b\u0438\u043c\u0444\u043e\u043c\u044b \u0425\u043e\u0434\u0436\u043a\u0438\u043d\u0430"],"prefix":"10.21320","volume":"9","author":[{"given":"Elena Andreevna","family":"Demina","sequence":"first","affiliation":[{"name":"NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u044b\u0439 \u0446\u0435\u043d\u0442\u0440 \u0438\u043c. \u041d.\u041d. \u0411\u043b\u043e\u0445\u0438\u043d\u0430\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041a\u0430\u0448\u0438\u0440\u0441\u043a\u043e\u0435 \u0448., \u0434. 24, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 115478"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8834","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"18076","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<1::AID-CNCR2820470102>3.0.CO;2-2"},{"key":"18077","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-12505-3"},{"key":"18078","unstructured":"Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Oncol. 2008;19(Suppl 4): Abstract 118."},{"key":"18079","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511"},{"key":"18080","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2186"},{"key":"18081","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8972"},{"key":"18082","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07740.x"},{"key":"18083","doi-asserted-by":"publisher","DOI":"10.3390\/toxins3070848"},{"key":"18084","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"18085","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510026200"},{"key":"18086","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0488"},{"key":"18087","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2736.2736"},{"key":"18088","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-2469"},{"key":"18089","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-097014"},{"key":"18090","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-3694"},{"key":"18091","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3969"},{"key":"18092","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"18093","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.798868"},{"key":"18094","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"18095","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.0543"},{"key":"18096","unstructured":"Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: Diagnosis, incidence, and management. Clin Adv Hematol Oncol. 2008;6(6):455\u201367."},{"key":"18097","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.06.008"},{"key":"18098","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-430918"},{"key":"18099","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.069393"},{"key":"18100","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.083048"},{"key":"18101","unstructured":"Perrot A, Monjanel H, Bouabdallah R, et al. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French name patient program experience in 241 patients. Haematologica. 2014;99(s1):498, abstr. S1293."},{"key":"18102","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.134213"},{"key":"18103","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08037.x"},{"key":"18104","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.2099.2099"},{"key":"18105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3308"},{"key":"18106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.12.257"},{"key":"18107","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026454831340"},{"key":"18108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.582.582"},{"key":"18109","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"18110","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.394"},{"key":"18111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.06.006"},{"key":"18112","unstructured":"Moskowitz CH, Paszkiewicz-Kozik E, Nadamanee A, et al. Analysis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled study of brentuximab vedotin consolidation after autologous stem cell transplant. Hematol Oncol. 2015;33:165, abstr. 120."},{"key":"18113","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"18114","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8519"},{"key":"18115","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.11.315"},{"key":"18116","unstructured":"Bonthapally V, Ma E, Viviani S, et al. Healthcare utilization in the AETHERA trial: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post-ASCT. Hematol Oncol. 2015;33:193, abstr. 177."},{"key":"18117","unstructured":"Kuruvilla J, Connors JM, Sawas A, et al. A phase 1 study of brentuximab vedotin (BV) and bendamustine (B) in relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large T-cell lymphoma (ALCL). Hematol Oncol. 2015;33:148, abstr. 090."},{"key":"18118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.6832"},{"key":"18119","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712443076"}],"container-title":["Clinical Oncohematology"],"original-title":[],"link":[{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/509\/471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/509\/471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:25:22Z","timestamp":1764501922000},"score":1,"resource":{"primary":{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/view\/509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.21320\/2500-2139-2016-9-4-398-405","relation":{},"ISSN":["2500-2139","1997-6933"],"issn-type":[{"type":"electronic","value":"2500-2139"},{"type":"print","value":"1997-6933"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}